SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Inhibikase Therapeutics, Inc. (IKT) News

Follow Inhibikase Therapeutics, Inc. (IKT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol IKT Asset equity Sector Markets 90 days 1 Last 1.38 Updated Sep 08, 2026, 08:43 PM UTC Open live news feed Open IKT chart & news
L Inhibikase updates presentation, highlights Phase 3 IKT-001 timelines Inhibikase updated its corporate presentation to highlight progress on the Phase 3 IKT-001 program and anticipated clinical timelines. REGULATION | Sep 08, 2026, 08:43 PM UTC L Inhibikase Therapeutics Q2 EPS $(0.11), Inline Inhibikase Therapeutics (NASDAQ: IKT ) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year. EARNINGS | Aug 11, 2026, 08:16 PM UTC L IKT - Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity IKT - Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity EARNINGS | Aug 11, 2026, 08:01 PM UTC L IKT Inhibikase Therapeutics announces FDA orphan drug designation granted to ikt-001 for the treatment of pah IKT Inhibikase Therapeutics announces FDA orphan drug designation granted to ikt-001 for the treatment of pah REGULATION | Jul 23, 2026, 12:00 PM UTC H Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Tuesday. Shares of Danaher Corp (NYSE: DHR ) fell sharply in pre-market trading following second-quarter results. Danaher p EARNINGS | Jul 21, 2026, 12:01 PM UTC L Inhibikase Therapeutics' treatment of PAH granted FDA orphan designation Inhibikase... REGULATION | Jul 16, 2026, 09:03 PM UTC